In 2019, the FDA shared preliminary results from its study of Xeljanz highlighting data connecting the drug with blood clotting problems. The agency further reported 45 patient deaths among people who took 10 mg of Xeljanz twice-daily. As a result of these findings, the FDA required Pfizer to add a black box warning to its Xeljanz product labels, Pfizer did not warn about blood clot risks prior to the placement of this black box warning, which was ultimately added in July 2019.
In February 2021, the Food and Drug Administration (FDA) reported on clinical trials showing Xeljanz was also associated with serious heart-related problems and cancer. According to the FDA, both the 5mg and 10mg doses of Xeljanz caused a higher risk of these injuries.
Xeljanz use has been linked to the following health conditions:
Congestive heart failure
Lung cancer (links established for non-smokers only)
Deep Vein Thrombosis (DVT)
Damages for Xeljanz are greatly dependent on the type and severity of your injuries, but we expect a multi-district litigation (MDL) to handle these matters on a national scale. You may be entitled to financial compensation for:
Past, present and future medical expenses
Other non-economic damages
Past, present and future pain and suffering
People may be eligible to file Xeljanz lawsuits if they or a loved one took the drug for rheumatoid arthritis, psoriatic arthritis or ulcerative colitis and suffered blood clots, cardiovascular problems or cancer. FDA safety alerts in 2019 and 2021 warned that Xeljanz may increase the risk of blood clots, heart problems, death and cancer.
If you have questions about whether you qualify for compensation from Xeljanz, Contact us immediately to see if you qualify for financial compensation.
Don't Wait Any Longer. Contact Us Today For HELP!
PO Box 5876
Lake Charles, Louisiana 70605